Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine

INTRODUCTION: Lasmiditan is a selective serotonin (5-HT1F) receptor agonist approved in the US for the acute treatment ofmigraine in adults. This phase I, open-label, two-cohort study assessed the pharmacokinetics (PK), safety, and tolerability of lasmiditan in patients with migraine aged 6 to <...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Pharmacokinet
Hlavní autoři: Tsai, Max, Nery, Emel Serap Monkul, Kerr, Lisa, Khanna, Rashna, Komori, Mika, Dennehy, Ellen B., Wilbraham, Darren, Winner, Paul
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2021
Témata:
Original Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8195962/
https://ncbi.nlm.nih.gov/pubmed/33565026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-020-00966-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky